<DOC>
	<DOCNO>NCT01706159</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate effect recombinant factor XIII ( rFXIII ) administer subject mild moderate active ulcerative colitis ( UC ) .</brief_summary>
	<brief_title>A Placebo-controlled Trial With rFXIII Administered Subjects With Mild Moderate Active Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Diagnosis ulcerative colitis least 3 month time initial diagnosis . The diagnosis must confirm historical endoscopy histology . The severity disease must confirm endoscopy screen Currently receive oral aminosalicylates approve dos least 2g/day least 6 week . Doses oral aminosalicylates stable least two week prior dose ( Visit 2 ) Diagnosis UC limit rectum ( ulcerative proctitis , define less 15 cm anal verge ) Requiring hospitalisation current episode severe UC Use biologic therapy treatment UC within 12 week prior dose ( Visit 2 ) Treatment failures antitumour necrosis factoralfa ( antiTNFa ) agent ( e.g . infliximab , adalimumab ) Use immunosuppressant agent ( e.g . azathioprine ) within 4 week prior dose ( Visit 2 ) Use corticosteroid ( oral , intravenous ( i.v . ) , intramuscular ( i.m . ) , rectal ) within 14 day prior dose ( Visit 2 ) Use enema ( corticosteroid aminosalicylate ) within 14 day prior screen ( Visit 1 ) Use cyclosporine , tacrolimus , Dpenicillamine , leflunomide , methotrexate , mycophenolate mofetil , thalidomide within 4 week prior dose ( Visit 2 ) Currently receive total parenteral nutrition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>